SCHEMBL25317209

SCHEMBL25317209

O=S(=O)(c1ccccn1)n1cccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTR6 P50406 3/20 0.43
CYP3A4 P08684 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PKLR P30613 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GRM4 Q14833 1/20 0.41
NFE2L2 Q16236 3/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
LOX P28300 1/20 0.38
GLO1 Q04760 1/20 0.38
SLC40A1 Q9NP59 1/20 0.38
PSEN1 P49768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28965976 0.74 CA1 (0.42) PKML3MBTL1CA1CA2MET
SCHEMBL1673906 0.73 KDM4E (0.64) PKMKDM4EL3MBTL1NFE2L2MEN1
SCHEMBL1847833 0.73 PKM (0.56) PKMKDM4ECYP3A4L3MBTL1PKLR
SCHEMBL4444519 0.73 PKM (0.42) PKMKDM4EHTR6CYP3A4L3MBTL1
SCHEMBL6616459 0.72 TSHR (0.56) PKMKDM4ECYP3A4L3MBTL1PKLR
SCHEMBL329498 0.72 KDM4E (0.52) PKMKDM4EL3MBTL1NFE2L2MEN1
SCHEMBL23025 0.70 KDM4E (0.55) PKMKDM4EL3MBTL1NFE2L2MEN1
SCHEMBL34548 0.70 KDM4E (0.50) PKMKDM4EL3MBTL1NFE2L2POLB
SCHEMBL24214242 0.70 KDM4E (0.50) PKMKDM4EL3MBTL1NFE2L2MEN1
SCHEMBL323373 0.70 KDM4E (0.50) PKMKDM4EL3MBTL1NFE2L2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767311-B2 Acid secretion inhibitor and use thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-09-26 US disclosed
US-20230192650-A1 NOVEL ACID SECRETION INHIBITOR AND USE THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767311-B2 Acid secretion inhibitor and use thereof SLC10A2, SLC10A1, ASIC1 PKM 3537/4885KDM4E 3961/4885HTR6 3588/4885
US-20230192650-A1 NOVEL ACID SECRETION INHIBITOR AND USE THEREOF SLC10A2, SLC10A1, ASIC1 PKM 3512/4885KDM4E 4072/4885HTR6 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.